Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Internal medicine

• Publication date

  2002-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2169/INTERNALMEDICINE.41.1118PMID 12521199
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias

  2002cited by this paper
• Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement

  2000cited by this paper
• Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia.

  2000cited by this paper
• The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

  2000cited by this paper
• Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study.

  1999cited by this paper
• A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.

  1999cited by this paper
• A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis.

  1999cited by this paper
• NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future.

  1999cited by this paper
• Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent , Pirfenidone Results of a Prospective , Open-label Phase II Study

  1999cited by this paper
• Classification and recent advances in idiopathic interstitial pneumonia.

  1998cited by this paper
• Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP.

  1998cited by this paper
• Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification.

  1998cited by this paper
• Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.

  1998cited by this paper
• Idiopathic pulmonary fibrosis: a need for treatment with drugs other than corticosteroids--a role for antifibrotic agents?

  1997cited by this paper
• Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients

  1997cited by this paper
• Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders.

  1997cited by this paper
• Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease

  1997cited by this paper
• Approaches to the treatment of pulmonary fibrosis.

  1995cited by this paper
• Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis.

  1994cited by this paper
• Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial.

  1991cited by this paper
• A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis.

  1986cited by this paper

• Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives

  2024cites this paper
• Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment

  2023cites this paper
• A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease

  2022cites this paper
• Patología respiratoria

  2022cites this paper
• Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis

  2022cites this paper
• Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis

  2022cites this paper
• Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond

  2022cites this paper
• The Treatment of Lung Involvement in Systemic Sclerosis

  2021cites this paper
• Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients

  2020cites this paper
• The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease

  2019cites this paper
• TGF-β1 - A truly transforming growth factor in fibrosis and immunity.

  2019cites this paper
• Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis

  2018cites this paper
• Body size‐adjusted dose analysis of pirfenidone in patients with interstitial pneumonia

  2018cites this paper
• Anti-fibrotic nintedanib—a new opportunity for systemic sclerosis patients?

  2018cites this paper
• Lung Disease in Rheumatoid Arthritis

  2018cites this paper
• Safer approaches to therapeutic modulation of TGF‐&bgr; signaling for respiratory disease

  2018cites this paper
• Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis

  2017cites this paper
• Interstitial lung disease in systemic sclerosis: current and future treatment

  2017cites this paper
• Is pirfenidone effective for idiopathic pulmonary fibrosis?

  2017cites this paper
• Management of the Rheumatoid Arthritis Patient with Interstitial Lung Disease

  2017influential citation
• Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial

  2017cites this paper
• Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy

  2016cites this paper
• Strategy for treatment of fibrosis in systemic sclerosis: Present and future

  2016cites this paper
• Pharmacotherapy of IPF Using Antifibrotic Compounds

  2016cites this paper
• Update on diagnosis and treatment of idiopathic pulmonary fibrosis

  2015cites this paper
• Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis

  2015cites this paper
• Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis

  2015cites this paper
• All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.

  2015cites this paper
• Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis

  2015cites this paper
• Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine

  2015influential citation
• The Core Evidence

  2015cites this paper
• Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?

  2015cites this paper
• Interstitial lung disease in rheumatoid arthritis: Current concepts in pathogenesis, diagnosis and therapeutics

  2015cites this paper
• Sobre el tratamiento de la enfermedad pulmonar intersticial en artritis reumatoide

  2015cites this paper
• Pirfenidone: an orphan drug for treating idiopathic pulmonary fibrosis

  2015cites this paper
• Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.

  2015cites this paper
• Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis

  2015cites this paper
• Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review

  2015cites this paper
• Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis

  2014cites this paper
• Pirfenidone for the treatment of idiopathic pulmonary

  2014cites this paper
• Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.

  2014cites this paper
• Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis

  2014cites this paper
• Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis

  2014cites this paper
• The treatment of idiopathic pulmonary fibrosis

  2014cites this paper
• Pirfenidone for the treatment of idiopathic pulmonary fibrosis

  2014influential citation
• Pharmacokinetics, Safety and Tolerability of Pirfenidone and its Major Metabolite after Single and Multiple Oral Doses in Healthy Chinese Subjects under Fed Conditions

  2013cites this paper
• New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research

  2013cites this paper
• S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose

  2013cites this paper
• Follistatin Is Induced by Ionizing Radiation and Potentially Predictive of Radiosensitivity in Radiation-Induced Fibrosis Patient Derived Fibroblasts

  2013cites this paper
• Pirfenidone: A Novel Agent for the Treatment of Idiopathic Pulmonary Fibrosis

  2013cites this paper
• Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.

  2013cites this paper
• Pirfenidone treatment of idiopathic pulmonary fibrosis

  2012cites this paper
• Inhibitory Effects of Pirfenidone on Dendritic Cells and Lung Allograft Rejection

  2012cites this paper
• Progression of renal disease pathogenetic aspects and treatment options

  2012cites this paper
• Treatment of interstitial lung diseases associated with connective tissue diseases

  2012cites this paper
• Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis

  2012cites this paper
• Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19

  2012cites this paper
• Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β.

  2012cites this paper
• Scleroderma therapy: clinical overview of current trends and future perspective

  2012cites this paper
• Clinical trials in idiopathic pulmonary fibrosis: update and perspectives

  2011cites this paper
• Pirfenidone

  2011cites this paper
• The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

  2011cites this paper
• Pirfenidona: una puerta abierta a la esperanza en la fibrosis pulmonar idiopática

  2011cites this paper
• Idiopathic Pulmonary Fibrosis

  2011cites this paper
• American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management

  2011cites this paper
• Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

  2011cites this paper
• Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?

  2011cites this paper
• Pirfenidone in idiopathic pulmonary fibrosis.

  2010cites this paper
• Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management

  2010cites this paper
• Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis

  2010cites this paper
• Pirfenidone: an anti-fibrotic therapy for progressive kidney disease

  2010cites this paper
• Targeted therapy for systemic sclerosis: how close are we?

  2010cites this paper
• Comparative Study of Oral Azathioprine and Intravenous Cyclophosphamide Pulses in the Treatment of Idiopathic Pulmonary Fibrosis

  2010cites this paper
• Pirfenidone (PIRESPA^|^reg;)

  2010cites this paper
• [Comparative study between oral azathioprine and intravenous cyclophosphamide pulses in the treatment of idiopathic pulmonary fibrosis].

  2010cites this paper
• Modifizierung einer Pirfenidonbehandlung für Patienten mit Fibrose

  2009cites this paper
• Modification du traitement par pirfénidone pour les patients souffrant de fibrose

  2009cites this paper
• Treatment of idiopathic interstitial pneumonias

  2009cites this paper
• Pirfenidone is renoprotective in diabetic kidney disease.

  2009cites this paper
• Recent Advances in the Treatment of Systemic Sclerosis

  2009cites this paper
• Advances in understanding of idiopathic pulmonary fibrosis.

  2009cites this paper
• Pirfenidone in idiopathic pulmonary fibrosis

  2009cites this paper
• La fibrose pulmonaire idiopathique

  2009cites this paper
• Effect of pirfenidone on renal tubulointerstitial fibrosis

  2009cites this paper
• New developments in the therapy of pulmonary fibrosis.

  2009cites this paper
• Role of collagen deposition in lymphatic tissues and immune reconstruction during HIV-1 and SIV infections

  2009cites this paper
• Development and Validation of an Improved LC Method for the Simultaneous Determination of Pirfenidone and Its Carboxylic Acid Metabolite in Human Plasma

  2009cites this paper
• Alveolar macrophage dysregulation in Hermansky-Pudlak syndrome type 1.

  2009cites this paper
• Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults.

  2009cites this paper
• Interstitial lung disease guideline

  2008cites this paper
• Pharmacotherapy in patients with idiopathic pulmonary fibrosis.

  2008cites this paper
• The Role of TGF-β in Radiation and Chemotherapy Induced Pulmonary Fibrosis: Inhibition of TGF-β as a Novel Therapeutic Strategy

  2008cites this paper
• Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens.

  2008cites this paper
• Pharmacokinetics and clinical effects of pirfenidone administered intravenously in horses.

  2008cites this paper
• Pharmacotherapy in patients with idiopathic pulmonary fibrosis

  2008cites this paper
• Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.

  2008cites this paper
• and the Irish Thoracic Society Thoracic Society of Australia and New Zealand Thoracic Society in collaboration with the Interstitial lung disease guideline: the British

  2008cites this paper
• Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis

  2008cites this paper
• Review: New perspectives in the treatment of idiopathic pulmonary fibrosis

  2008cites this paper
• The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

  2008cites this paper